外分泌膵機能不全（EPI）治療・診断の世界市場（～2026年）

• 英文タイトル：Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY11893
• 出版社/出版日：QYResearch / 2020年11月25日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、95ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：医療機器・消耗品

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料は外分泌膵機能不全（EPI）治療・診断のグローバル市場について調査・分析したレポートです。種類別（治療、診断（血液検査・内視鏡超音波検査・磁気共鳴画像法（MRI）・CTスキャン））市場規模、用途別（病院、外来手術センター、専門クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別外分泌膵機能不全（EPI）治療・診断の競争状況、市場シェア
・世界の外分泌膵機能不全（EPI）治療・診断市場：種類別市場規模 2015年-2020年（治療、診断（血液検査・内視鏡超音波検査・磁気共鳴画像法（MRI）・CTスキャン））
・世界の外分泌膵機能不全（EPI）治療・診断市場：種類別市場規模予測 2021年-2026年（治療、診断（血液検査・内視鏡超音波検査・磁気共鳴画像法（MRI）・CTスキャン））
・世界の外分泌膵機能不全（EPI）治療・診断市場：用途別市場規模 2015年-2020年（病院、外来手術センター、専門クリニック）
・世界の外分泌膵機能不全（EPI）治療・診断市場：用途別市場規模予測 2021年-2026年（病院、外来手術センター、専門クリニック）
・北米の外分泌膵機能不全（EPI）治療・診断市場分析：米国、カナダ
・ヨーロッパの外分泌膵機能不全（EPI）治療・診断市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの外分泌膵機能不全（EPI）治療・診断市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の外分泌膵機能不全（EPI）治療・診断市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの外分泌膵機能不全（EPI）治療・診断市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：AbbVie、Allergan、Nordmark Arzneimittel、Digestive Care、Janssen Pharmaceuticals、Cilian、Anthera Pharmaceuticals、AzurRx Biopharma
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Exocrine pancreatic insufficiency (EPI) refers to the condition wherein the body is unable to produce sufficient amounts of exocrine pancreatic enzymes, thus leading to difficulties in digesting food properly. The condition occurs due to the lack of sufficient enzymes necessary for fat digestion, amylases for starch digestion, and proteases for protein digestion.

Market Analysis and Insights: Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market
The global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market size is projected to reach US$ 3613.4 million by 2026, from US$ 3460.6 million in 2020, at a CAGR of 4.1%% during 2021-2026.

Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Scope and Market Size
Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
AbbVie
Allergan
Nordmark Arzneimittel
Digestive Care
Janssen Pharmaceuticals
Cilian
Anthera Pharmaceuticals
AzurRx Biopharma

Market segment by Type, the product can be split into
Therapeutics
Diagnostics (Blood Tests, Endoscopic Ultra-sonography, Magnetic Resonance Imaging (MRI), and CT Scanning)
Market segment by Application, split into
Hospitals
Ambulatory Surgical Centers
Specialty Clinics

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue
1.4 Market by Type
1.4.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Therapeutics
1.4.3 Diagnostics (Blood Tests, Endoscopic Ultra-sonography, Magnetic Resonance Imaging (MRI), and CT Scanning)
1.5 Market by Application
1.5.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Ambulatory Surgical Centers
1.5.4 Specialty Clinics
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Perspective (2015-2026)
2.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Growth Trends by Regions
2.2.1 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Historic Market Share by Regions (2015-2020)
2.2.3 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Growth Strategy
2.3.6 Primary Interviews with Key Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Players by Market Size
3.1.1 Global Top Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Players by Revenue (2015-2020)
3.1.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share by Players (2015-2020)
3.1.3 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Concentration Ratio
3.2.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in 2019
3.3 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Key Players Head office and Area Served
3.4 Key Players Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Solution and Service
3.5 Date of Enter into Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Historic Market Size by Type (2015-2020)
4.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2015-2020)
5.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size (2015-2020)
6.2 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Key Players in North America (2019-2020)
6.3 North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2015-2020)
6.4 North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2015-2020)

7 Europe
7.1 Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size (2015-2020)
7.2 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Key Players in Europe (2019-2020)
7.3 Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2015-2020)
7.4 Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2015-2020)

8 China
8.1 China Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size (2015-2020)
8.2 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Key Players in China (2019-2020)
8.3 China Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2015-2020)
8.4 China Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2015-2020)

9 Japan
9.1 Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size (2015-2020)
9.2 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Key Players in Japan (2019-2020)
9.3 Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2015-2020)
9.4 Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size (2015-2020)
10.2 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2015-2020)
10.4 Southeast Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2015-2020)

11 India
11.1 India Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size (2015-2020)
11.2 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Key Players in India (2019-2020)
11.3 India Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2015-2020)
11.4 India Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size (2015-2020)
12.2 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Key Players in Central & South America (2019-2020)
12.3 Central & South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2015-2020)
12.4 Central & South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 AbbVie
13.1.1 AbbVie Company Details
13.1.2 AbbVie Business Overview
13.1.3 AbbVie Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
13.1.4 AbbVie Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2015-2020))
13.1.5 AbbVie Recent Development
13.2 Allergan
13.2.1 Allergan Company Details
13.2.2 Allergan Business Overview
13.2.3 Allergan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
13.2.4 Allergan Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2015-2020)
13.2.5 Allergan Recent Development
13.3 Nordmark Arzneimittel
13.3.1 Nordmark Arzneimittel Company Details
13.3.2 Nordmark Arzneimittel Business Overview
13.3.3 Nordmark Arzneimittel Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
13.3.4 Nordmark Arzneimittel Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2015-2020)
13.3.5 Nordmark Arzneimittel Recent Development
13.4 Digestive Care
13.4.1 Digestive Care Company Details
13.4.2 Digestive Care Business Overview
13.4.3 Digestive Care Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
13.4.4 Digestive Care Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2015-2020)
13.4.5 Digestive Care Recent Development
13.5 Janssen Pharmaceuticals
13.5.1 Janssen Pharmaceuticals Company Details
13.5.2 Janssen Pharmaceuticals Business Overview
13.5.3 Janssen Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
13.5.4 Janssen Pharmaceuticals Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2015-2020)
13.5.5 Janssen Pharmaceuticals Recent Development
13.6 Cilian
13.6.1 Cilian Company Details
13.6.2 Cilian Business Overview
13.6.3 Cilian Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
13.6.4 Cilian Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2015-2020)
13.6.5 Cilian Recent Development
13.7 Anthera Pharmaceuticals
13.7.1 Anthera Pharmaceuticals Company Details
13.7.2 Anthera Pharmaceuticals Business Overview
13.7.3 Anthera Pharmaceuticals Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
13.7.4 Anthera Pharmaceuticals Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2015-2020)
13.7.5 Anthera Pharmaceuticals Recent Development
13.8 AzurRx Biopharma
13.8.1 AzurRx Biopharma Company Details
13.8.2 AzurRx Biopharma Business Overview
13.8.3 AzurRx Biopharma Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Introduction
13.8.4 AzurRx Biopharma Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2015-2020)
13.8.5 AzurRx Biopharma Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Key Market Segments
Table 2. Key Players Covered: Ranking by Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue
Table 3. Ranking of Global Top Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Therapeutics
Table 6. Key Players of Diagnostics (Blood Tests, Endoscopic Ultra-sonography, Magnetic Resonance Imaging (MRI), and CT Scanning)
Table 7. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Regions (2015-2020)
Table 11. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Growth Strategy
Table 17. Main Points Interviewed from Key Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Players
Table 18. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue by Players (2015-2020) (Million US$)
Table 19. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Players (2015-2020)
Table 20. Global Top Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics as of 2019)
Table 21. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Solution and Service
Table 24. Date of Enter into Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 27. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size Share by Type (2015-2020)
Table 28. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Market Share by Type (2021-2026)
Table 29. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size Share by Application (2015-2020)
Table 30. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 31. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size Share by Application (2021-2026)
Table 32. North America Key Players Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share (2019-2020)
Table 34. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 35. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Type (2015-2020)
Table 36. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 37. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Application (2015-2020)
Table 38. Europe Key Players Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share (2019-2020)
Table 40. Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Type (2015-2020)
Table 42. Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Application (2015-2020)
Table 44. China Key Players Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (2019-2020) (Million US$)
Table 45. China Key Players Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share (2019-2020)
Table 46. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 47. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Type (2015-2020)
Table 48. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 49. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Application (2015-2020)
Table 50. Japan Key Players Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share (2019-2020)
Table 52. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Type (2015-2020)
Table 54. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share (2019-2020)
Table 58. Southeast Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Type (2015-2020)
Table 60. Southeast Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Application (2015-2020)
Table 62. India Key Players Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (2019-2020) (Million US$)
Table 63. India Key Players Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share (2019-2020)
Table 64. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 65. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Type (2015-2020)
Table 66. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 67. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share (2019-2020)
Table 70. Central & South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Type (2015-2020)
Table 72. Central & South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Application (2015-2020)
Table 74. AbbVie Company Details
Table 75. AbbVie Business Overview
Table 76. AbbVie Product
Table 77. AbbVie Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 78. AbbVie Recent Development
Table 79. Allergan Company Details
Table 80. Allergan Business Overview
Table 81. Allergan Product
Table 82. Allergan Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 83. Allergan Recent Development
Table 84. Nordmark Arzneimittel Company Details
Table 85. Nordmark Arzneimittel Business Overview
Table 86. Nordmark Arzneimittel Product
Table 87. Nordmark Arzneimittel Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 88. Nordmark Arzneimittel Recent Development
Table 89. Digestive Care Company Details
Table 90. Digestive Care Business Overview
Table 91. Digestive Care Product
Table 92. Digestive Care Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 93. Digestive Care Recent Development
Table 94. Janssen Pharmaceuticals Company Details
Table 95. Janssen Pharmaceuticals Business Overview
Table 96. Janssen Pharmaceuticals Product
Table 97. Janssen Pharmaceuticals Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 98. Janssen Pharmaceuticals Recent Development
Table 99. Cilian Company Details
Table 100. Cilian Business Overview
Table 101. Cilian Product
Table 102. Cilian Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 103. Cilian Recent Development
Table 104. Anthera Pharmaceuticals Company Details
Table 105. Anthera Pharmaceuticals Business Overview
Table 106. Anthera Pharmaceuticals Product
Table 107. Anthera Pharmaceuticals Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 108. Anthera Pharmaceuticals Recent Development
Table 109. AzurRx Biopharma Business Overview
Table 110. AzurRx Biopharma Product
Table 111. AzurRx Biopharma Company Details
Table 112. AzurRx Biopharma Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Business (2015-2020) (Million US$)
Table 113. AzurRx Biopharma Recent Development
Table 114. Research Programs/Design for This Report
Table 115. Key Data Information from Secondary Sources
Table 116. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Type: 2020 VS 2026
Figure 2. Therapeutics Features
Figure 3. Diagnostics (Blood Tests, Endoscopic Ultra-sonography, Magnetic Resonance Imaging (MRI), and CT Scanning) Features
Figure 4. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Application: 2020 VS 2026
Figure 5. Hospitals Case Studies
Figure 6. Ambulatory Surgical Centers Case Studies
Figure 7. Specialty Clinics Case Studies
Figure 8. Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Report Years Considered
Figure 9. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Regions: 2020 VS 2026
Figure 11. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Players in 2019
Figure 14. Global Top Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue in 2019
Figure 16. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Bottom-up and Top-down Approaches for This Report
Figure 24. Data Triangulation
Figure 25. Key Executives Interviewed

以下、関連資料のご紹介

膀胱がん治療・診断の世界市場（～2026年）

Global Bladder Cancer Therapeutics and Diagnostics Market Size, Status and Forecast 2020-2026
MRC2-11QY11116 2020年11月25日 95Pages
当調査資料は膀胱がん治療・診断のグローバル市場について調査・分析したレポートです。種類別（化学療法、免疫療法、放射線療法、その他）市場規模、用途別（病院、腫瘍治療センター、外来手術センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア...

ヒトマイクロバイオームベース薬剤・診断の世界市場（～2026年）

Global Human Microbiome Based Drugs and Diagnostics Market Size, Status and Forecast 2020-2026
MRC2-11QY12253 2020年11月25日 92Pages
当調査資料はヒトマイクロバイオームベース薬剤・診断のグローバル市場について調査・分析したレポートです。種類別（治療、診断）市場規模、用途別（臨床研究所、病院、外科センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国...

結核（TB）診断の世界市場（～2026年）

Global Tuberculosis (TB) Diagnostics Market Size, Status and Forecast 2020-2026
MRC2-11QY04901 2020年11月20日 96Pages
当調査資料は結核（TB）診断のグローバル市場について調査・分析したレポートです。種類別（塗抹顕微鏡検査、分子検査、マントーツベルクリン検査、培養、薬剤感受性検査、PLHIV用LF-LAM）市場規模、用途別（診断研究所、病院）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス...

医療関連感染（HAI）診断の世界市場（～2026年）

Global Hospital Acquired Infections (HAI) Diagnostics Market Size, Status and Forecast 2020-2026
MRC2-11QY12230 2020年11月25日 93Pages
当調査資料は医療関連感染（HAI）診断のグローバル市場について調査・分析したレポートです。種類別（分子診断検査、その他体外診断検査）市場規模、用途別（菌血症（BSI）、尿路感染症（UTI）、手術部位感染症（SSI）、肺炎、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イ...

DNA検査/診断の世界市場（～2026年）

Global DNA Testing/Diagnostics Market Size, Status and Forecast 2020-2026
MRC2-11QY11701 2020年11月25日 129Pages
当調査資料はDNA検査/診断のグローバル市場について調査・分析したレポートです。種類別（PCR診断、ISH診断、NGSDNA診断）市場規模、用途別（病院、医学研究、薬理ゲノミクス診断検査、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、...

心房細動（AF）診断の世界市場（～2026年）

Global Atrial Fibrillation (AF) Diagnostics Market Size, Status and Forecast 2020-2026
MRC2-11QY10916 2020年11月25日 91Pages
当調査資料は心房細動（AF）診断のグローバル市場について調査・分析したレポートです。種類別（心電図（ECG）、心エコー図（エコー）、経食道心エコー検査（TEE）、胸部X線、血液検査、ストレス検査、電気的活動検査）市場規模、用途別（カーディオセンター、大病院、心臓専門医療企業）市場規模、地域別（北米、...

心臓ポイントオブケア（POC）診断の世界市場（～2026年）

Global Cardiology Point-of-Care (POC) Diagnostics Market Size, Status and Forecast 2020-2026
MRC2-11QY11267 2020年11月25日 97Pages
当調査資料は心臓ポイントオブケア（POC）診断のグローバル市場について調査・分析したレポートです。種類別（心臓代謝モニタリング、心臓代謝診断）市場規模、用途別（専門診断センター、病院/救命救急センター、研究所、在宅医療）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イ...

子宮頸がん治療法・診断の世界市場（～2026年）

Global Therapies and Diagnostics for Cervical Cancer Market Size, Status and Forecast 2020-2026
MRC2-11QY04840 2020年11月20日 98Pages
当調査資料は子宮頸がん治療法・診断のグローバル市場について調査・分析したレポートです。種類別（パパニコロウ塗抹検査、コルポスコピー検査、ECC手順）市場規模、用途別（製薬会社、病院および診療所、民間および政府の研究所、学術機関）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギ...

呼吸器疾患検査/診断の世界市場（～2026年）

Global Respiratory Disease Testing/Diagnostics Market Size, Status and Forecast 2020-2026
MRC2-11QY04489 2020年11月20日 132Pages
当調査資料は呼吸器疾患検査/診断のグローバル市場について調査・分析したレポートです。種類別（画像検査、呼吸測定、血液ガス検査、その他）市場規模、用途別（病院、医師クリニック、臨床検査室、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日...

膵臓がん治療薬の世界市場（～2026年）

Global Pancreatic Cancer Therapeutics Market Size, Status and Forecast 2020-2026
MRC2-11QY04150 2020年11月20日 91Pages
当調査資料は膵臓がん治療薬のグローバル市場について調査・分析したレポートです。種類別（生物学、化学療法、標的療法、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オースト...

強皮症診断・治療の世界市場（～2026年） Market Analysis and Insights: Global Scleroderma Diagnostics and Therapeutics Market The global Scleroderma Diagnostics and Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Scleroderma Diagnostics and Thera…
クラミジア感染症診断・治療の世界市場（～2026年） The chlamydia infection diagnostics and therapeutics market unveils high potential owing to the rapidly rising patient pool and vast untapped opportunities. Market Analysis and Insights: Global Chlamydia Infection Diagnostics and Therapeutics Market The global Chlamydia Infection Diagnostics and The…
膵臓がん治療薬の世界市場（～2026年） Pancreatic cancer therapy is recommended by clinicians for early detection of cancer. Pancreatic cancer generally diagnosed at a later stage, since the symptoms are not easily detected or diagnosed. Factors such as, chronic inflammation of the pancreas (pancreatitis), diabetes, smoking, and obesity …
膀胱がん治療・診断の世界市場（～2026年） The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the inner…
脳卒中診断・治療の世界市場（～2026年） Stroke refers to the brain attack. Stroke occurs when the supply of blood to the brain is either interrupted or reduced. Increasing number of mergers and acquisitions, rapid product launches, and rise in number of collaborations and partnerships are some of the latest trends that have been observed …